Dr. Anna Banerji, the Director of Global and Indigenous Health at Continuing Professional Development, Faculty of Medicine, University of Toronto, is a paediatric infectious, tropical disease specialist and global health specialist. She has trained in Toronto, Ottawa, Montreal, and Harvard University, where she completed her MPH in International Health.

Dr. Banerji’s clinical and research focus has been on vulnerable children, especially Indigenous and refugees. In 2007 she created the Immigrant Health and Infectious Disease Clinic, a clinic for immigrant and refugee children. Currently she is the pediatric consultant at COSTI where she assesses newly arrived Refugee children. In 2009 she created the Canadian Refugee Health Conference which evolved with their American counter parts to become North American Refugee Health Conference in 2012. In 2014 she created the inaugural Indigenous Health Conference: Challenging Health Inequities.

She have been studying lower respiratory tract infections in Inuit children for almost two decades and the results of her work has led to increased awareness of the public health risks for LRTI and has resulted in changes to the CPS guidelines for the prevention of respiratory syncytial virus in the Inuit. She was the P.I. for the largest prospective surveillance of LRTI across the Canadian Arctic based out of nine hospitals. Dr. Banerji uses a human rights framework for her work, research and education and is often an advocate for vulnerable populations. In January 2012, she was inducted into the Order of Ontario.

Recent Publications

  1. Banerji, A, Canadian Paediatric Society, First Nations, Inuit and Métis Health Committee. Scabies. Paediatr Child Health. 2015;20 (7):395-402. . PubMed PMID:26527041 PubMed Central PMC4614097.
  2. Evans, AB, Kulik, D, Banerji, A, Boggild, A, Kain, KC, Abdelhaleem, M et al.. Imported pediatric malaria at the Hospital for Sick Children, Toronto, Canada: a 16 year review. BMC Pediatr. 2014;14 :251. doi: 10.1186/1471-2431-14-251. PubMed PMID:25281037 PubMed Central PMC4287547.
  3. Banerji, A, Panzov, V, Young, M, Lee, BE, Mamdani, M, Giles, BL et al.. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut. Can. Respir. J. ;21 (3):185-9. . PubMed PMID:24367792 PubMed Central PMC4128465.
  4. Banerji, A, Panzov, V, Robinson, J, Young, M, Ng, K, Mamdani, M et al.. The cost of lower respiratory tract infections hospital admissions in the Canadian Arctic. Int J Circumpolar Health. 2013;72 :. doi: 10.3402/ijch.v72i0.21595. PubMed PMID:23967411 PubMed Central PMC3748437.
  5. Banerji, A, Canadian Paediatric Society, First Nations, Inuit and Métis Health Committee. Preventing unintentional injuries in Indigenous children and youth in Canada. Paediatr Child Health. 2012;17 (7):393-4. . PubMed PMID:23904787 PubMed Central PMC3448544.
  6. Persaud, N, Maguire, JL, Lebovic, G, Carsley, S, Khovratovich, M, Randall Simpson, JA et al.. Association between serum cholesterol and eating behaviours during early childhood: a cross-sectional study. CMAJ. 2013;185 (11):E531-6. doi: 10.1503/cmaj.121834. PubMed PMID:23775611 PubMed Central PMC3735770.
  7. Ford-Jones, L, Levin, L, Schneider, R, Daneman, D, Social Pediatrics Working Group. A new social pediatrics elective--a tool for moving to life course developmental health. J. Pediatr. 2012;160 (3):357-358.e2. doi: 10.1016/j.jpeds.2011.11.043. PubMed PMID:22329871 .
  8. Paes, BA, Mitchell, I, Banerji, A, Lanctôt, KL, Langley, JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can. Respir. J. ;18 (2):e10-9. . PubMed PMID:21499597 PubMed Central PMC3084427.
  9. Tam, DY, Banerji, A, Paes, BA, Hui, C, Tarride, JE, Lanctôt, KL et al.. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ. 2009;12 (4):361-70. doi: 10.3111/13696990903442155. PubMed PMID:19900071 .
  10. Banerji, A, Lanctôt, KL, Paes, BA, Masoud, ST, Tam, DY, Macdonald, WA et al.. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr. Infect. Dis. J. 2009;28 (8):702-6. doi: 10.1097/INF.0b013e31819df78e. PubMed PMID:19461555 .
Search PubMed

Affiliations & Other Activities

  • Pediatric Infectious Disease, Pediatrics, St. Michael’s Hospital
  • Associate Professor, Pediatrics, University of Toronto
  • Associate Professor, Dalla Lana School of Public Health, University of Toronto
  • Associate, Centre for International Health, University of Toronto
  • Pediatric Infectious Disease, Infectious Disease, Hospital for Sick Children (cross appointment)